Close menu

November 3rd, 2021 | 11:03 CET

MorphoSys, Defence Therapeutics, Formycon - Biotech and pharma offer potential for the portfolio

  • Biotechnology
Photo credits:

The pharmaceutical industry alone has annual sales of over EUR 1,000 billion worldwide and helps people overcome their illnesses. Since the Corona pandemic, biotech and pharma companies are even more in the spotlight. If a company manages to develop a blockbuster, big profits also beckon to shareholders. BioNTech is currently a prime example of this, even if the share has consolidated in the meantime. Where there are high profits, there is also a higher risk. The road to the development and approval of a drug is long, and failure is also possible. As people are getting older and diseases are rising, it makes sense to invest in these areas. Today we analyze three potential candidates.

time to read: 4 minutes | Author: Armin Schulz

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    MorphoSys - Good news

    The former stock market darling MorphoSys owns the most extensive antibody library globally, and from this, new drugs have been developed repeatedly through collaborations. The licensing income generated in this way allowed the Company to grow, and the biotech company was to slowly become a pharmaceutical company. Since then, this major undertaking has caused difficulties within the Company. These became even greater with the decision to take over Constellation Pharmaceuticals because large parts of the licensing income were given out of hand to finance the takeover.

    Recently, the Company was able to come up with a series of good news. On October 20, it was announced that the first patient with immunoglobulin A nephropathy, a chronic kidney disease, had been treated in the course of a Phase II trial. This prompted the analysts at Berenberg to give the share a price target of EUR 124. On November 2, there was a small preview of the 3rd quarter figures, which will be presented on November 11. Compared to Q2, sales of the cancer drug Monjuvi increased by EUR 3.7 million to EUR 18.6 million.

    In addition, the Company has two drugs from Constellation Pharmaceuticals in the pipeline, which are in their phase III trials. Since October 19, the stock has risen from EUR 37.10 to EUR 42.26. To leave the downtrend, a closing price above EUR 43.25 would be necessary. That would also mean crossing the 50 moving average from the bottom to the top. The next resistance would then be at EUR 51.60.

    Defence Therapeutics - Success in the fight against breast cancer

    The Canadian biotech company Defence Therapeutics is breaking new ground in drug delivery. Whereas conventional drugs using antibody-drug conjugates (ADC) have repeatedly shown ineffective drug delivery, using the Company's proprietary Accum platform, the drug is delivered precisely to the cell nucleus that needs it. This intracellular ADC routing improves outcomes by a factor of 10, and the platform technology, which all approved ADCs can use, significantly enhances the therapeutic effect.

    The first results are available for the AccuVAC-IN002 Corona vaccine, which is administered intranasally. It was previously tested with success in mice and subsequently in rabbits. Furthermore, a program is underway to develop a vaccine against HPV to prevent cervical cancer. Since June 29, the collaboration with the Institut Curie in Paris has been ongoing to investigate the therapeutic efficacy of the Accum-T-DM1-ADC compound against breast cancer. On October 13, the Company reported that the efficacy of Accum variants of T-deruxtecan against breast cancer was improved 5-fold.

    The Company is currently preparing a Phase I trial of its cancer vaccine AccuVAC-D0002. The product pipeline is full, and the more successful trials that have been completed, the more exciting the stock becomes. It is currently at 6.10 Canadian dollars (CAD) and could form a double bottom. If that succeeds, the all-time high at CAD 8.15 should be tested. The upward trend remains intact as long as there has been no closing price below CAD 6.00. Support below this mark is at CAD 3.39. This would then close the price gap.

    Formycon - FDA reviews approval

    The biotech company Formycon develops biosimilars after patent expiry of the original drug, i.e. biological drugs as an alternative to the originals. The focus is on therapies in ophthalmology, immunology and chronic diseases. The Company sees itself as a partner for large pharmaceutical and generics companies. The Company started shortly after the outbreak of the Corona pandemic with the development of an antibody fusion protein to block cell infection by the virus completely. It is currently in preclinical development.

    A potential profit driver for the future is FYB201, the biosimilar to the eye drug Lucentis. On October 4, acceptance of FYB201 for approval by the FDA was confirmed, and approval has also been filed in Europe. The decision is expected to be made in August 2022. On October 19, a licensing and collaboration agreement was signed with SCG Cell Therapy, giving the Asian Company exclusive rights to Covid's drug FYB207 in Asia, excluding Japan. If the drug is approved in the region, up to EUR 63.5 million in one-time payments and royalties in the low double-digit percentage range of sales await.

    The Company has a broad range of drugs in the pipeline. Management and the advisory board are experts in biosimilar development. The stock has been able to attract some attention due to its research in the Corona area. If FYB201 is approved, up to EUR 100 million per year could be flushed into the Company's coffers. Since the beginning of August, the share has been moving sideways between EUR 47.00 and EUR 53.90. An upward breakout makes a test of EUR 64 likely.

    The potential of biotech and pharmaceutical companies is great. If you jump on the bandwagon too late, you will have to endure significant setbacks, as in the case of MorphoSys. If you invest early, as in the case of Defence Therapeutics, you can quickly have a multiplier in your portfolio if the Company is successful. Formycon uses existing drugs and reproduces them on a biological basis. The principle promises big profits if approved. However, the share has already started up well due to the development of a Corona drug.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author

    Related comments:

    Commented by Stefan Feulner on July 17th, 2024 | 06:30 CEST

    BioNTech, Cardiol Therapeutics, Bayer - Prepared for the next wave

    • Biotechnology
    • Biotech
    • Pharma

    The assassination attempt on former and possibly future US President Donald Trump was clearly the dominant topic at the weekend, causing both gold and the largest cryptocurrencies to surge at the start of the week. Still largely unnoticed, however, the COVID-19 figures are rising again, especially in the United States, which could halt the downward spiral for vaccine manufacturers such as BioNTech/Pfizer and Moderna.


    Commented by Fabian Lorenz on July 11th, 2024 | 06:55 CEST

    Shares with breakthrough potential? Evotec, Varta, and Carbon Done Right Developments

    • Sustainability
    • Pharma
    • Biotechnology
    • renewableenergies
    • CarbonCredits

    Evotec is currently going from strength to strength. Yesterday, a partnership with pharmaceutical giant Pfizer boosted the share price. Will the resistance at EUR 10 now finally fall? There has also been positive news for Varta recently. Is the possible collaboration with Porsche a game changer? Analysts have a clear opinion on this matter. At Carbon Done Right Developments, investors are eagerly awaiting the AIM listing. Once it happens, the share price could explode, as the Company is working on an ecosystem within a billion-dollar market. Should you position yourself now? In any case, all three companies are working towards a breakthrough.


    Commented by André Will-Laudien on July 11th, 2024 | 06:45 CEST

    Mega rally on the cards - 500% plus is likely too low an estimate! Evotec, Desert Gold, Cogia, VCI Global, and Lufthansa

    • Mining
    • Gold
    • Commodities
    • Biotechnology
    • airline

    The stock market keeps rising and rising - this much is revealed by the ever-new highs of prominent indices such as the NASDAQ 100, S&P 500, or the Nikkei index. However, a closer look reveals some inconsistencies. For example, only 6% of all traded stocks are currently reaching new highs, while over 70% of all listed stocks have fallen since the beginning of the year. In short, global liquidity is aggregated in just a few blockbuster stocks, with the rest being left behind. Such bubbles already occurred in 1999, 2007, and 2015, followed by a 25% to 50% correction. When exactly this will happen, no one knows, but the party is likely to continue for a while due to high liquidity. Gold and silver are in the process of forming interesting breakout formations. Now is the time to pick the cherries!